These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1337 related articles for article (PubMed ID: 27668885)
41. Design of novel dopamine D Zhang C; Li Q; Meng L; Ren Y J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624 [TBL] [Abstract][Full Text] [Related]
42. Pharmacophore modeling, 3D-QSAR and molecular docking studies of benzimidazole derivatives as potential FXR agonists. Sindhu T; Srinivasan P J Recept Signal Transduct Res; 2014 Aug; 34(4):241-53. PubMed ID: 25072161 [TBL] [Abstract][Full Text] [Related]
43. Effect of hydrophobic and hydrogen bonding interactions on the potency of ß-alanine analogs of G-protein coupled glucagon receptor inhibitors. Venugopal PP; Das BK; Soorya E; Chakraborty D Proteins; 2020 Feb; 88(2):327-344. PubMed ID: 31443129 [TBL] [Abstract][Full Text] [Related]
44. Discovery of potential Aurora-A kinase inhibitors by 3D QSAR pharmacophore modeling, virtual screening, docking, and MD simulation studies. Swamy P M G; Abbas N; Dhiwar PS; Singh E; Ghara A; Das A J Biomol Struct Dyn; 2023 Jan; 41(1):125-146. PubMed ID: 34809538 [TBL] [Abstract][Full Text] [Related]
45. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors. Liu G; Wang W; Wan Y; Ju X; Gu S Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616 [TBL] [Abstract][Full Text] [Related]
46. Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors. Tripuraneni NS; Azam MA J Mol Model; 2015 Nov; 21(11):289. PubMed ID: 26499496 [TBL] [Abstract][Full Text] [Related]
47. Identification of potential CRAC channel inhibitors: Pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach. Bhuvaneshwari S; Sankaranarayanan K SAR QSAR Environ Res; 2019 Feb; 30(2):81-108. PubMed ID: 30773908 [TBL] [Abstract][Full Text] [Related]
48. In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics. Larif S; Salem CB; Hmouda H; Bouraoui K J Mol Graph Model; 2014 Sep; 53():1-12. PubMed ID: 25064438 [TBL] [Abstract][Full Text] [Related]
49. Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors. Kalyaanamoorthy S; Chen YP J Mol Graph Model; 2013 Jul; 44():44-53. PubMed ID: 23732305 [TBL] [Abstract][Full Text] [Related]
50. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer. Ren JX; Li CP; Zhou XL; Cao XS; Xie Y J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799 [TBL] [Abstract][Full Text] [Related]
51. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation. Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195 [TBL] [Abstract][Full Text] [Related]
52. Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure-activity relationship (q-RASAR) and pharmacophore modeling. Khatun S; Dasgupta I; Islam R; Amin SA; Jha T; Dhaked DK; Gayen S Mol Divers; 2024 Aug; 28(4):2197-2215. PubMed ID: 38871969 [TBL] [Abstract][Full Text] [Related]
53. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations. Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408 [TBL] [Abstract][Full Text] [Related]
54. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation. Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603 [TBL] [Abstract][Full Text] [Related]
55. Docking and 3D QSAR Studies on Substituted Cyclobutylphenyl Quinoline Derivatives as Inhibitors of Bacterial DNA Gyrase. Wani RR; Chaudhari HK Curr Comput Aided Drug Des; 2018; 14(4):322-337. PubMed ID: 29766821 [TBL] [Abstract][Full Text] [Related]
56. First universal pharmacophore model for hERG1 K Durdagi S; Erol I; Salmas RE; Patterson M; Noskov SY J Mol Graph Model; 2017 Jun; 74():153-170. PubMed ID: 28499268 [TBL] [Abstract][Full Text] [Related]
57. Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors. Lotfi B; Mebarka O; Khan SU; Htar TT J Biomol Struct Dyn; 2024 Jul; 42(10):5308-5320. PubMed ID: 37334701 [TBL] [Abstract][Full Text] [Related]
58. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis. Kumar A; Roy S; Tripathi S; Sharma A J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809 [TBL] [Abstract][Full Text] [Related]
59. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors. Hassanzadeh M; Bagherzadeh K; Amanlou M J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186 [TBL] [Abstract][Full Text] [Related]
60. Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor - a novel target to prevent Alzheimer's disease. Choubey SK; Jeyakanthan J J Recept Signal Transduct Res; 2018 Jun; 38(3):266-278. PubMed ID: 29932788 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]